Maxim Group Issues Positive Forecast for INmune Bio (NASDAQ:INMB) Stock Price

INmune Bio (NASDAQ:INMB) had its price target increased by Maxim Group from $22.00 to $30.00 in a research report report published on Thursday,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Several other equities analysts also recently weighed in on the stock. Scotiabank increased their price target on shares of INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Tuesday. RODMAN&RENSHAW raised shares of INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Alliance Global Partners started coverage on shares of INmune Bio in a report on Monday, October 21st. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Rodman & Renshaw began coverage on INmune Bio in a research report on Tuesday, January 28th. They set a “buy” rating and a $23.00 price target on the stock. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $22.80.

INmune Bio Stock Performance

INmune Bio stock opened at $9.30 on Thursday. The business’s 50-day simple moving average is $6.44 and its two-hundred day simple moving average is $6.11. The company has a market cap of $206.18 million, a PE ratio of -4.27 and a beta of 1.87. INmune Bio has a fifty-two week low of $4.32 and a fifty-two week high of $14.74.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INMB. Financial Advocates Investment Management grew its position in shares of INmune Bio by 17.4% during the 3rd quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock valued at $73,000 after acquiring an additional 2,000 shares during the period. Praetorian PR LLC boosted its position in INmune Bio by 61.0% during the third quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock worth $4,209,000 after purchasing an additional 295,800 shares in the last quarter. State Street Corp grew its holdings in INmune Bio by 35.1% in the third quarter. State Street Corp now owns 226,428 shares of the company’s stock valued at $1,220,000 after purchasing an additional 58,838 shares during the period. Jane Street Group LLC purchased a new stake in shares of INmune Bio in the third quarter valued at approximately $79,000. Finally, XTX Topco Ltd acquired a new position in shares of INmune Bio during the 3rd quarter worth approximately $249,000. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.